The following is a summary of “Physician Preferences in Using Novel Digital Devices for the Management of Atrial Fibrillation ...

ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...